CBS News Covers AXIM Biotech’s Patent Filing for Controlled-Release Chewing Gum to Provide Treatment for Opioid Addiction
NEW YORK, Feb. 21, 2018 (GLOBE NEWSWIRE) --
AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTCQB:AXIM), a world leader in cannabinoid research and development, today announced that CBS News covered the Company’s recent patent filing on a controlled-release chewing gum to provide treatment for opioid addiction.
In June 2017, AXIM Biotech announced that the Company filed with the United States Patent and Trademark Office (USPTO) a patent application (U.S. Patent Application Serial Number 62/410,469) on an invention concerning a chewing gum with controlled release of cannabinoids and opioid agonists and/or antagonists for addiction and/or dependence treatment. This chewing gum may also potentially be used for treatment of chronic pain.
“Opioid addiction is killing 115 people per day and has accounted for the majority of the 64,000 drug overdose deaths in the United States in 2016. By comparison, more than 58,000 U.S. military died in the Vietnam War,” said George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM Biotech. “In the hope of helping find solutions, opioid addiction therapy depends on a variety of techniques. One of them is the replacement therapy, where an opioid is replaced with another less potent and less addictive opioid that curbs the craving and reduces withdrawal symptoms, while maintaining the person’s mental state such that the person is still able to function normally.”
By potentially providing replacement opioids such as opioid agonists and/or antagonists and cannabinoids in a functional chewing gum, users may avoid adverse effects caused by smoking, injection and other delivery methods. The act of chewing is also known to be neuroprotective, destressing, since it induces the release of reward hormones such as dopamine and serotonin, and improves oral health.
AXIM® Biotechnologies, Inc. (OTC:AXIM) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew®, a CBD-based controlled release chewing gum, and MedChew Rx, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. We prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, please visit www.AXIMBiotech.com.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein.
AXIM® Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).
Public Relations Contact
Chief Executive Officer
P. +1888 829-0070
Corporate Contact Info
North American Address:
18 East 50th Street, 5 Floor
New York, NY 10022
+1 844 294 6246
Released February 21, 2018